Clinical Trial
doi: 10.1053/j.seminoncol.2005.07.017.
Brief communication: a new combination in the treatment of advanced pancreatic cancer
Affiliations
- PMID: 16360004
- DOI: 10.1053/j.seminoncol.2005.07.017
Item in Clipboard
Clinical Trial
Brief communication: a new combination in the treatment of advanced pancreatic cancer
Semin Oncol.
2005 Dec.
Abstract
Single-agent gemcitabine is currently the standard treatment for advanced pancreatic cancer. A majority of recent phase III trials have shown either marginal or no improvement in survival using gemcitabine in combination with other chemotherapeutic and novel agents. Our group recently reported that the combination of gemcitabine with erlotinib was associated with a significant prolongation of survival and improvement in progression-free survival in advanced pancreatic cancer.
Similar articles
-
Recent updates on the role of chemotherapy in pancreatic cancer.Semin Oncol. 2005 Aug;32(4 Suppl 6):S1-3. doi: 10.1053/j.seminoncol.2005.06.022. Semin Oncol. 2005. PMID: 16143160 Review.
-
Pancreatic cancer: an update.Curr Oncol Rep. 2007 May;9(3):170-6. doi: 10.1007/s11912-007-0018-z. Curr Oncol Rep. 2007. PMID: 17430687 Review.
-
Novel advances in pancreatic cancer treatment.Expert Rev Anticancer Ther. 2008 Jun;8(6):993-1002. doi: 10.1586/14737140.8.6.993. Expert Rev Anticancer Ther. 2008. PMID: 18533808 Review.
-
Survival benefit with the combination of docetaxel, gemcitabine and erlotinib in advanced and/or metastatic pancreatic cancer patients.Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1776-81. doi: 10.5754/hge10455. Epub 2011 Jul 15. Hepatogastroenterology. 2011. PMID: 21940348
-
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.Cancer Chemother Pharmacol. 2007 Jul;60(2):295-303. doi: 10.1007/s00280-006-0389-0. Epub 2006 Dec 6. Cancer Chemother Pharmacol. 2007. PMID: 17149608 Clinical Trial.
Cited by
-
Pancreatic cancer: challenges and opportunities.BMC Med. 2018 Nov 22;16(1):214. doi: 10.1186/s12916-018-1215-3. BMC Med. 2018. PMID: 30463539 Free PMC article.
-
Pancreatic cancer.Annu Rev Pathol. 2008;3:157-88. doi: 10.1146/annurev.pathmechdis.3.121806.154305. Annu Rev Pathol. 2008. PMID: 18039136 Free PMC article. Review.
-
Human amniotic fluid mesenchymal stem cells attenuate pancreatic cancer cell proliferation and tumor growth in an orthotopic xenograft mouse model.Stem Cell Res Ther. 2022 Jun 3;13(1):235. doi: 10.1186/s13287-022-02910-3. Stem Cell Res Ther. 2022. PMID: 35659367 Free PMC article.
-
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.Mol Cancer Ther. 2011 Jan;10(1):3-8. doi: 10.1158/1535-7163.MCT-10-0893. Epub 2010 Dec 6. Mol Cancer Ther. 2011. PMID: 21135251 Free PMC article. Clinical Trial.
-
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.Clin Cancer Res. 2008 Aug 15;14(16):5142-9. doi: 10.1158/1078-0432.CCR-07-4072. Clin Cancer Res. 2008. PMID: 18698032 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
